The study, published in Annals of the Rheumatic Diseases, found that patients receiving Humira for 12 weeks experienced a significant improvement in spine and sacroiliac joint inflammation compared with those who received the placebo. Approximately 36 percent of patients taking Humira reported experiencing at least a 40 percent improvement in pain, compared to 15 percent taking the placebo.
The effects also appeared to have long-term benefits for patients. Nearly one-quarter of the Humira group experienced clinical remission after three months, compare with four percent of the placebo group.
Related Articles on Pain Management:
ASIPP Releases Opioid Guidelines
Study: Pediatric Pain Rehab Boosts Self-Management Skills
PainCare to Open Twelfth Location
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.